Based on the Concord Biotech Limited stock forecast from 0 analysts, the average analyst target price for Concord Biotech Limited is not available over the next 12 months. Concord Biotech Limited’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Concord Biotech Limited is Slightly Bullish , which is based on 9 positive signals and 6 negative signals. At the last closing, Concord Biotech Limited’s stock price was INR 2,237.25. Concord Biotech Limited’s stock price has changed by +9.50% over the past week, +7.36% over the past month and +52.80% over the last year.
No recent analyst target price found for Concord Biotech Limited
No recent average analyst rating found for Concord Biotech Limited
Company Overview Concord Biotech Limited
Concord Biotech Limited, a biopharma company, engages in the research and development, manufacturing, marketing, and sale of pharmaceutical products in India and internationally. The company provides fermentation based active pharmaceutical ingredients in immunosuppressants, anti-bacterial, oncology, antifungal, and other therapeutic areas. It also offers tacrolimus, mycophenolate mofetil, mycophenolate sodium, cyclosporine, sirolimus, and pimecrolimus for immunosuppressants therapeutic segment; temsirolimus, everolimus, romidepsin, mitomycin, midostaurin, dactinomycin, staurosporin, mitoguazone, and everolimus premix for oncology therapeutic segment; mupirocin, mupirocin calcium, polymyxin B sulfate, fidaxomicin, vancomycin hydrochloride, and teicoplanin for anti-bacterial applications; anidulafungin, caspofungi, micafungin sodium, amphotericin B, and nystatin for anti-fungal therapeutic segment; and lovastatin, pravastatin sodium, and enzymes for other applications. In addition, it provides contract research and manufacturing services in the areas of fermentation and semi-synthesis products. Concord Biotech Limited was incorporated in 1984 and is based in Ahmedabad, India. Read Less
Concord Biotech Limited, a biopharma company, engages in the research and development, manufacturing, marketing, and sale of pharmaceutical products in India and internationally. The company provides fermentation based active pharmaceutical ingredients in immunosuppressants, anti...Read More
Frequently Asked Questions About Concord Biotech Limited (CONCORDBIO:NSE) Stock
Stock Target Advisor's fundamental analysis for Concord Biotech Limited's stock is Slightly Bullish .
CONCORDBIO:NSE stock's dividend yield is 0.41%.
Our analysis grades CONCORDBIO:NSE stock's dividend yield at A+. This means that CONCORDBIO:NSE stock's dividend yield is above 100% of the stocks in the Biotechnology sector in the NSE exchange.
Based on this CONCORDBIO:NSE may be a good dividend stock for its sector.
Unfortunately we do not have enough data on CONCORDBIO:NSE's stock to indicate what its average analyst target is.
CONCORDBIO:NSE stock's Price/Earning ratio is 68.97.
Our analysis grades CONCORDBIO:NSE stock's Price / Earning ratio at F. This means that CONCORDBIO:NSE stock's Price/Earning ratio is above 64% of the stocks in the Biotechnology sector in the NSE exchange.
Based on this CONCORDBIO:NSE may be a overvalued for its sector.
The last closing price of CONCORDBIO:NSE's stock was INR 2,237.25.
The most recent market capitalization for CONCORDBIO:NSE is INR 227.24B.
Unfortunately we do not have enough analyst data on CONCORDBIO:NSE's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Concord Biotech Limited's stock.
As per our most recent records Concord Biotech Limited has 1,377 Employees.
Concord Biotech Limited's registered address is 16th Floor, B-Wing, Ahmedabad, India, 380015.
You can get more information about it from Concord Biotech Limited's website at https://www.concordbiotech.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Low volatility
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
Superior risk adjusted returns
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior return on assets
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
Superior capital utilization
The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
High Gross Profit to Asset Ratio
This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.
Superior return on equity
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Overpriced on cashflow basis
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Low Dividend Growth
This stock has shown below median dividend growth in the previous 5 years compared to its sector.
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About Concord Biotech Limited (CONCORDBIO:NSE) Stock
Stock Target Advisor's fundamental analysis for Concord Biotech Limited's stock is Slightly Bullish .
CONCORDBIO:NSE stock's dividend yield is 0.41%.
Our analysis grades CONCORDBIO:NSE stock's dividend yield at A+. This means that CONCORDBIO:NSE stock's dividend yield is above 100% of the stocks in the Biotechnology sector in the NSE exchange.
Based on this CONCORDBIO:NSE may be a good dividend stock for its sector.
Unfortunately we do not have enough data on CONCORDBIO:NSE's stock to indicate what its average analyst target is.
CONCORDBIO:NSE stock's Price/Earning ratio is 68.97.
Our analysis grades CONCORDBIO:NSE stock's Price / Earning ratio at F. This means that CONCORDBIO:NSE stock's Price/Earning ratio is above 64% of the stocks in the Biotechnology sector in the NSE exchange.
Based on this CONCORDBIO:NSE may be a overvalued for its sector.
The last closing price of CONCORDBIO:NSE's stock was INR 2,237.25.
The most recent market capitalization for CONCORDBIO:NSE is INR 227.24B.
Unfortunately we do not have enough analyst data on CONCORDBIO:NSE's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Concord Biotech Limited's stock.
As per our most recent records Concord Biotech Limited has 1,377 Employees.
Concord Biotech Limited's registered address is 16th Floor, B-Wing, Ahmedabad, India, 380015.
You can get more information about it from Concord Biotech Limited's website at https://www.concordbiotech.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for CONCORDBIO:NSE !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
